Bestina
$ 11,00 – $ 29,00Price range: $ 11,00 through $ 29,00
Charboleps
$ 6,00 – $ 14,00Price range: $ 6,00 through $ 14,00
Brafix
$ 11,00 – $ 29,00Price range: $ 11,00 through $ 29,00
Brafix is an effective medication specifically designed to protect the stomach lining from damage caused by long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). By mimicking the action of natural prostaglandins, this treatment helps maintain a healthy gastric environment and reduces excessive acid production. It is primarily indicated for individuals at high risk of developing gastric ulcers while undergoing chronic pain management therapy. The active components in Brafix work to strengthen the protective mucosal barrier, preventing the formation of painful lesions in the digestive tract. Consistent use of this medication ensures superior gastrointestinal defense, allowing patients to continue their necessary anti-inflammatory treatments with greater comfort.
Active substance: Herbal
SKU:
Brafix
Categories: Herbals, Woman's Health
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Brafix belongs to a class of targeted therapeutic agents known as BRAF kinase inhibitors. It is designed to selectively inhibit mutated forms of the BRAF serine-threonine kinase enzyme, which play a central role in driving abnormal cellular proliferation. The medication is dispensed in accordance with applicable federal and state regulations.
Treatment with Brafix requires confirmation of a specific gene mutation in tumor tissues prior to initiating therapy. Clinical evaluation and ongoing laboratory monitoring are essential throughout the treatment period to manage potential adverse reactions and maintain therapeutic oversight.
| Parameter | Specification |
|---|---|
| Active ingredient (INN) | Dabrafenib (as mesylate) |
| Primary purpose | Targeted therapy for BRAF V600 mutation-positive malignancies |
| Route of administration | Oral |
| Dosage form | Oral capsule |
| Prescription status | Dispensed in accordance with applicable federal and state regulations |
| Food requirement | Take on an empty stomach (1 hour before or 2 hours after a meal) |
Clinical Overview and Pharmacological Profile
Main uses and mechanism
How the drug works: The mechanism of action of Brafix centers on the competitive inhibition of the BRAF kinase enzyme. Mutations in the BRAF gene, such as the V600E or V600K substitution, lead to constitutive activation of the downstream MAPK (mitogen-activated protein kinase) signaling pathway. This pathway includes MEK and ERK proteins, which stimulate cell growth, survival, and differentiation. By binding to the ATP-binding pocket of the mutated BRAF kinase, Brafix suppresses cellular phosphorylation events, resulting in the inhibition of tumor cell growth and the induction of apoptosis in mutation-positive cell lines.
Main uses: Brafix is indicated for the treatment of patients with unresectable or metastatic melanoma carrying confirmed BRAF V600E or V600K mutations. Additionally, it is prescribed as part of targeted regimens for metastatic non-small cell lung cancer (NSCLC) harboring the BRAF V600E mutation, and for advanced solid tumors or thyroid cancers with demonstrated BRAF mutation positivity. Confirmation of BRAF V600 mutation status using an FDA-approved diagnostic test is mandatory before initiating therapy, as the drug is not effective in wild-type BRAF malignancies.
Dosing, administration, and kinetics
Dosing schedule: The standard dosage of Brafix is administered orally twice daily, approximately 12 hours apart, unless otherwise modified by the prescribing clinician. Capsules must be swallowed whole with water and should not be chewed, crushed, or opened. Co-administration with food significantly alters systemic exposure; therefore, doses must be taken at least 1 hour before a meal or at least 2 hours following food intake. Dose interruptions or reductions are routinely executed based on individual patient tolerability and toxicity grading.
What happens in the body: Following oral administration, maximum plasma concentrations (Cmax) of Brafix are achieved within approximately 2 hours under fasting conditions. Co-administration with high-fat, high-calorie meals reduces Cmax by approximately 50% and overall systemic exposure (AUC) by 31%. The drug binds extensively to human plasma proteins (greater than 99%). Hepatic metabolism is predominant, mediated primarily by cytochrome P450 enzymes CYP2C8 and CYP3A4, yielding active metabolites including hydroxy-dabrafenib and desmethyl-dabrafenib. Elimination occurs mainly via feces (approximately 71%) and secondarily via urine (approximately 23%). The mean terminal elimination half-life is approximately 8 hours.
Safety Information and Patient Guidance
Safety profile and precautions
Adverse reactions: Clinical trials and post-marketing surveillance indicate that adverse effects associated with Brafix vary depending on whether it is administered as monotherapy or in combination with other agents. Frequently reported side effects include pyrexia (fever), fatigue, headache, hyperkeratosis, alopecia, arthralgia, rash, and papilloma. Laboratory abnormalities may include hyperglycemia, hypophosphatemia, and elevated liver enzymes. Cutaneous squamous cell carcinoma and keratoacanthoma have been observed and require ongoing dermatologic surveillance.
Compatibility with other medicines: Strong inhibitors or inducers of CYP3A4 and CYP2C8 enzymes can significantly alter plasma concentrations of Brafix. Co-administration with strong CYP3A4 inducers (such as rifampin, carbamazepine, or St. John’s wort) may decrease therapeutic efficacy. Drugs that alter gastric pH, such as proton pump inhibitors or H2-receptor antagonists, may decrease drug solubility and absorption. Furthermore, Brafix can induce CYP3A4 and CYP2C19, potentially reducing the efficacy of hormonal contraceptives, warfarin, and dexamethasone. Non-hormonal barrier methods of contraception are recommended.
Important precautions: New primary cutaneous and non-cutaneous malignancies can develop during treatment. Patients should undergo dermatologic evaluation prior to therapy, every 2 months during therapy, and up to 6 months post-discontinuation. Severe febrile reactions, sometimes accompanied by severe rigors, dehydration, hypotension, and acute kidney injury, can occur. Brafix should be withheld if fever reaches 101°F (38.5°C) or higher. Monitoring for uveitis, iritis, hyperglycemia in diabetic patients, and glucose-6-phosphate dehydrogenase (G6PD) deficiency-related hemolytic anemia is necessary. Safety and effectiveness in pediatric populations have not been established.
Red flags: Immediate emergency medical evaluation is necessary if severe adverse events arise. Critical signs include a high fever exceeding 104°F (40°C), severe chills accompanied by low blood pressure or fainting, signs of major bleeding, sudden severe changes in vision or eye pain, widespread skin redness or blistering, or shortness of breath combined with swelling of the extremities.
If you skip a dose: If a scheduled dose of Brafix is missed, it should be taken as soon as remembered. However, if the time until the next scheduled dose is less than 6 hours, the missed dose must be skipped, and the regular dosing schedule resumed. Double doses should not be ingested to compensate for a missed dose.
Day-to-day use: Routine temperature checks at home are recommended to detect early signs of pyrexia. Adequate oral hydration should be maintained unless fluid restriction is clinically indicated. Skin should be protected from excessive direct sun exposure by using broad-spectrum sunscreens and protective clothing. Patients should keep a detailed log of any body temperature elevations or skin changes to present during regular oncology follow-up visits.
Storage and expiration: Brafix should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). The medication must be kept in its original bottle with the desiccant pouch intact to protect from moisture and light. Do not use past the expiration date printed on the container. Keep securely out of reach of children and pets.
Common questions
What should be done if a high fever develops during treatment?
If body temperature reaches 101°F (38.5°C) or higher, Brafix therapy should be temporarily paused and the healthcare provider notified promptly. Antipyretic medications may be recommended under medical direction. Treatment is typically resumed at the same or reduced dose once fever resolves completely for at least 24 hours.
How does food intake impact the absorption of this medication?
Food substantially decreases the rate and extent of absorption of Brafix. High-fat meals reduce peak blood levels by approximately half. To ensure consistent blood levels, the medication must strictly be taken on an empty stomach–either 1 hour before eating or 2 hours after a meal.
Are routine skin examinations required while taking this drug?
Yes, regular dermatologic examinations are required due to the risk of developing secondary skin lesions or cutaneous carcinomas. Baseline skin checks are conducted before starting therapy, followed by clinical evaluations every two months during treatment and for up to six months after stopping the drug.
How does this medication interact with hormonal birth control?
Brafix induces hepatic enzymes responsible for metabolizing steroid hormones, which can render oral contraceptives, patch devices, and hormonal implants less effective. Female patients of reproductive potential must use an effective non-hormonal method of contraception during treatment and for 2 weeks after the final dose.
Is routine blood work necessary during treatment?
Regular blood testing is standard clinical protocol. Diagnostics typically include monitoring blood glucose levels, serum electrolytes, liver enzyme panels, and complete blood counts to identify asymptomatic metabolic or organ changes early.
Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.
In accordance with FDA requirements.
Additional information
| Dosage |
60 caps |
|---|---|
| Package |
1 bottles ,2 bottles ,3 bottles |
| Ενεργός Ουσία |
Related products
Ayurslim
$ 71,00 – $ 199,00Price range: $ 71,00 through $ 199,00
Active substance: Ayurslim
More Details
This product has multiple variants. The options may be chosen on the product page
Diabecon
$ 57,00 – $ 345,00Price range: $ 57,00 through $ 345,00
Active substance: Diabecon
More Details
This product has multiple variants. The options may be chosen on the product page
Diarex
$ 54,00 – $ 236,00Price range: $ 54,00 through $ 236,00
Active substance: Diarex
More Details
This product has multiple variants. The options may be chosen on the product page
Haridra
$ 48,00
Active substance: Haridra
More Details
This product has multiple variants. The options may be chosen on the product page
Himplasia
$ 55,00 – $ 210,00Price range: $ 55,00 through $ 210,00
Active substance: Himplasia
More Details
This product has multiple variants. The options may be chosen on the product page
Hoodia
$ 80,00 – $ 294,00Price range: $ 80,00 through $ 294,00
Active substance: oxypregnane steroidal glycoside
More Details
This product has multiple variants. The options may be chosen on the product page
Liv.52 Drops
$ 50,00
Active substance: Chicory, The Caper Bush
More Details
This product has multiple variants. The options may be chosen on the product page
Lukol
$ 63,00 – $ 79,00Price range: $ 63,00 through $ 79,00
More Details
This product has multiple variants. The options may be chosen on the product page
